Abstract: The present disclosure describes a microfluidic chip for culturing and in vitro testing of 3D organotypic cultures. The tests may be performed directly on the organotypic culture in the microfluidic chip. The microfluidic chip includes at least one microfluidic unit which includes two fluidic compartments, such as upper and lower, separated by a permeable supporting structure, one or more access opening for the fluidic compartments, and a set of lids interchangeable with a set of insets. The permeable support structure serves as a support for the organotypic culture. The upper and lower compartments may include inlets and outlets which allow fluids to be perfused into the lower compartment and fluids to be perfused into the upper compartment. The access opening may be closed with a lid or accommodate an inset.

Abstract: The following disclosure discusses systems and methods of detecting and analyzing cutaneous conditions. According to one embodiment, a 2D image of the cutaneous condition and a set of 3D point clouds associated with the 2D image are captured using an image capturing device. The 2D image and the set of 3D point clouds are sent to a computing device. The computing device generates a 3D surface according to the set of 3D point clouds. Subsequently, the computing device receives a depth map for the 2D image based upon the 3D surface from another computing device such that the depth map comprises depth data for each pixel of the 2D image. The cutaneous condition may then be measured and analyzed based upon the depth map using the computing device.

Abstract: The is provided a compound of formula I or II or physiologically acceptable salts or solvates, or oxidised derivatives thereof: where R1 to R3, R13 and R14 are as defined herein. Also disclosed herein are methods of dyeing hair or (temporarily) tattooing the skin using the compounds of formula I or II (or physiologically acceptable salts or solvates, or oxidised derivatives thereof) in a suitable composition.

Abstract: The is provided a compound of formula I or II or physiologically acceptable salts or solvates, or oxidised derivatives thereof: where R1 to R3, R13 and R14 are as defined herein. Also disclosed herein are methods of dyeing hair or (temporarily) tattooing the skin using the compounds of formula I or II (or physiologically acceptable salts or solvates, or oxidised derivatives thereof) in a suitable composition.

Abstract: The following disclosure discusses systems and methods of detecting and analyzing cutaneous conditions. According to one embodiment, a 2D image of the cutaneous condition and a set of 3D point clouds associated with the 2D image are captured using an image capturing device. The 2D image and the set of 3D point clouds are sent to a computing device. The computing device generates a 3D surface according to the set of 3D point clouds. Subsequently, the computing device receives a depth map for the 2D image based upon the 3D surface from another computing device such that the depth map comprises depth data for each pixel of the 2D image. The cutaneous condition may then be measured and analyzed based upon the depth map using the computing device.

Abstract: The present disclosure describes a microfluidic chip for culturing and in vitro testing of 3D organotypic cultures. The tests may be performed directly on the organotypic culture in the microfluidic chip. The microfluidic chip includes at least one microfluidic unit which includes two fluidic compartments, such as upper and lower, separated by a permeable supporting structure, one or more access opening for the fluidic compartments, and a set of lids interchangeable with a set of insets. The permeable support structure serves as a support for the organotypic culture. The upper and lower compartments may include inlets and outlets which allow fluids to be perfused into the lower compartment and fluids to be perfused into the upper compartment. The access opening may be closed with a lid or accommodate an inset.

Abstract: The present invention relates to improved compositions for photodynamic therapy (PDT) for the selective destruction of malignant, diseased, or infected cells or infective agents without causing damage to normal cells. In an embodiment, the composition comprises a photosensitising agent coupled to a ligand, wherein the ligand selectively binds to a targeted receptor and comprises an isolated peptide molecule having less than 10 or 8 amino acids.